Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Gaschler-Markefski

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|September 29, 2011
How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approachFrank Fleischer, Birgit Gaschler-Markefski, Erich Bluhmki
Statistics in Medicine|July 7, 2009
A statistical model for the dependence between progression-free survival and overall survivalFrank Fleischer, Birgit Gaschler-Markefski, Erich Bluhmki
Neuroreport|June 15, 2004
Auditory stream segregation relying on timbre involves left auditory cortexSusann Deike, Birgit Gaschler-Markefski, André Brechmann, et al.
Cerebral Cortex (New York, N.Y. : 1991)|January 6, 2007
Working memory specific activity in auditory cortex: potential correlates of sequential processing and maintenanceAndré Brechmann, Birgit Gaschler-Markefski, Mandy Sohr, et al.
Oncotargets and Therapy|August 21, 2018
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 studyMartin Reck, Anders Mellemgaard, Silvia Novello, et al.
Anticancer Research|October 23, 2009
An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myelomaMartin Kropff, Joachim Kienast, Guido Bisping, et al.
Clinical Lung Cancer|June 5, 2012
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancerPeter M Ellis, Quincy S Chu, Natasha Leighl, et al.
Seeing and Perceiving|August 26, 2011
Anomalous Auditory Cortex Activations in Colored Hearing Synaesthetes: An fMRI-StudyBirgit Gaschler-Markefski, Gregor R Szycik, Christopher Sinke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 8, 2010
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trialMartin Sebastian, Martin Reck, Cornelius F Waller, et al.
ESMO Open|August 2, 2017
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|September 29, 2011
How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approachFrank Fleischer, Birgit Gaschler-Markefski, Erich Bluhmki
Statistics in Medicine|July 7, 2009
A statistical model for the dependence between progression-free survival and overall survivalFrank Fleischer, Birgit Gaschler-Markefski, Erich Bluhmki
Neuroreport|June 15, 2004
Auditory stream segregation relying on timbre involves left auditory cortexSusann Deike, Birgit Gaschler-Markefski, André Brechmann, et al.
Cerebral Cortex (New York, N.Y. : 1991)|January 6, 2007
Working memory specific activity in auditory cortex: potential correlates of sequential processing and maintenanceAndré Brechmann, Birgit Gaschler-Markefski, Mandy Sohr, et al.
Oncotargets and Therapy|August 21, 2018
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 studyMartin Reck, Anders Mellemgaard, Silvia Novello, et al.
Anticancer Research|October 23, 2009
An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myelomaMartin Kropff, Joachim Kienast, Guido Bisping, et al.
Clinical Lung Cancer|June 5, 2012
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancerPeter M Ellis, Quincy S Chu, Natasha Leighl, et al.
Seeing and Perceiving|August 26, 2011
Anomalous Auditory Cortex Activations in Colored Hearing Synaesthetes: An fMRI-StudyBirgit Gaschler-Markefski, Gregor R Szycik, Christopher Sinke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 8, 2010
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trialMartin Sebastian, Martin Reck, Cornelius F Waller, et al.
ESMO Open|August 2, 2017
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, et al.
Pageof 2